



10690802 6/16/06



chain nodes :

12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

8-12

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 7-11 8-9 10-11

exact/norm bonds :

5-7 6-9 7-8 7-10 7-11 8-9 8-12 10-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:Atom 12:CLASS 13:Atom 14:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 14:41:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 783 TO ITERATE

100.0% PROCESSED 783 ITERATIONS

0 ANSWERS

10690802 6/16/06


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:232851 CAPLUS
 DOCUMENT NUMBER: 144:489480
 TITLE: Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I
 AUTHOR(S): Jiang, Tao; Kuhen, Kelli L.; Wolff, Karen; Yin, Hong; Bieza, Kimberly; Caldwell, Jeremy; Bursulaya, Badry; Wu, Tom Yao-Hsiang; He, Yun
 CORPORATE SOURCE: Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA, 92121, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(8), 2105-2108
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A novel oxindole was discovered as a non-nucleoside HIV reverse transcriptase inhibitor via HTS using a cell-based assay. Systematic structural modifications were carried out to establish its SAR. These modifications led to the identification of oxindoles with low nanomolar potency for inhibiting HIV replication. These novel and potent oxindoles could serve as advanced leads for further optimizations.

IT 887131-16-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (Preparation of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors)

RN 887131-16-0 CAPLUS
 CN Spiro[cyclopropane-1,3'-[3H]indole]-2-carboxylic acid, 1',2'-dihydro-2'-oxo-5'-phenyl-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:368921 CAPLUS
 DOCUMENT NUMBER: 140:386004
 TITLE: Oxindoles for treatment of HIV infection, and preparation thereof
 INVENTOR(S): He, Yun; Jiang, Tao; Kuhen, Kelli L.; Ellis, David Archer; Wu, Baogen; Wu, Tom Yao-Hsiang; Bursulaya, Badry
 PATENT ASSIGNEE(S): IRM LLC, Bermuda; The Scripps Research Institute
 SOURCE: PCI Int. Appl., 84 pp.
 CODEN: PIXKX2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037247	A1	20040506	WO 2003-US33563	20031021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003286604	A1	20040513	AU 2003-286604	20031021
US 2004152755	A1	20040805	US 2003-690802	20031021
PRIORITY APPLN. INFO.:			US 2002-420481P	P 20021021
			US 2002-420482P	P 20021021
			WO 2003-US33563	W 20031021

OTHER SOURCE(S): MARPAT 140:386004
 GI




10690802 6/16/06

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:790474 CAPLUS
 DOCUMENT NUMBER: 133:350137
 TITLE: Preparation of indolinones as progesterone antagonists
 INVENTOR(S): Fensome, Andrew; Miller, Lori L.; Ullrich, John W.;
 Bender, Reinhold H. W.; Zhang, Puwen; Wrobel, Jay E.;
 Zhi, Lin; Jones, Todd K.; Marschke, Keith B.; Tegley,
 Christopher M.
 PATENT ASSIGNEE(S): American Home Products Corporation, USA; Ligand
 Pharmaceuticals, Inc.
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066556	A1	20001109	WO 2000-US11847	20000501
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6391907	B1	20020521	US 2000-552632	20000419
CA 2371638	AA	20001109	CA 2000-2371638	20000501
EP 1175398	A1	20020130	EP 2000-930289	20000501
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010215	A	20020213	BR 2000-10215	20000501
JP 2002543183	T2	20021217	JP 2000-615387	20000501
ZA 2001007631	A	20020515	ZA 2001-7631	20010917
NO 2001005379	A	20020103	NO 2001-5379	20011102
US 2002086874	A1	20020704	US 2001-14173	20011214
US 6608068	B2	20030819		
US 2003220388	A1	20031127	US 2003-456892	20030606
PRIORITY APPLN. INFO.:			US 1999-183058P	P 19990504
			US 2000-552632	A1 20000419
			WO 2000-US11847	W 20000501
			US 2001-14173	A3 20011214

OTHER SOURCE(S): MARPAT 133:350137
 GI


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I: R1, R2 = H, alkyl, OH, etc.; or R1 and R2 are joined to form a ring comprising CH2(CH2)nCH2, CH2CH2CH2CH2CH2, O(CH2)mCH2, etc.; or R1 and R2 comprise a double bond to CH=CH2, C(cycloalkyl), O, C(cycloether); n = 0-5; m = 1-4; R3 = H, OH, NH2, etc.; R4 = H, halo, CN, etc.; R5 = substituted Ph, (un)substituted 5-6 membered heterocyclic ring with 1-3 heteroatoms, indol-4-yl, etc.] which are antagonists of the progesterone receptor, and are useful in inducing contraception, and treating or preventing benign or malignant neoplastic disease, were prepared Thus, treating oxindole with Br2 in the presence of NaOAc in CHCl3 followed by reacting the resulting 5-bromo-2-indolinone with 3-nitrophenylboronic acid in the presence of Pd(PPh3)4 afforded I [R1-R4 = H; R5 = 3-O2NCGH4]. Biol. data for compds. I was given.

IT 304875-78-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indolinones as progesterone antagonists)

RN 304875-78-3 CAPLUS
 Spiro[cyclopropane-1,3'-(3H)indol]-2'-(1'H)-one, 5'-(3-chlorophenyl)- (9CI)
 (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:790350 CAPLUS
 DOCUMENT NUMBER: 133:350135
 TITLE: Preparation of oxospiro[cycloalkane-1,3'-indoline] derivatives and analogs as progesterone receptor antagonists
 INVENTOR(S): Grubb, Gary S.; Zhi, Lin; Jones, Todd K.; Tegley, Christopher M.; Fensome, Andrew; Miller, Lori L.; Ullrich, John W.; Bender, Reinhold H. W.; Zhang, Puwen; Wrobel, Jay E.; Edwards, James F.
 PATENT ASSIGNEE(S): American Home Products Corporation, USA; Ligand Pharmaceuticals, Inc.; et al.
 SOURCE: PCT Int. Appl., 135 pp.
 CODEN: PIXX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066167	A1	20001109	WO 2000-US11834	20000501
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6462032	B1	20021008	US 2000-552358	20000419
CA 2372595	AA	20001109	CA 2000-2372595	20000501
EP 1173212	A1	20020123	EP 2000-930287	20000501
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002543158	T2	20021217	JP 2000-615051	20000501
US 2003050288	A1	20030313	US 2002-153393	20020522
US 6544970	B2	20030408		
PRIORITY APPLN. INFO.:			US 1999-183052P	P 19990504
			US 2000-552358	A1 20000419
			WO 2000-US11834	W 20000501


OTHER SOURCE(S): MARPAT 133:350135
 GI

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 alkanyl, etc.; R4 = H, halo, alkyl, alkoxy, etc.; R5 = CGH4, 4- or 7-indolyl, 2-benzothienyl, etc.; R = OH, cyano, alkyl, alkoxy, etc.; n = 2-7; m = 2-5; p = 1-4] were prepd. E.g., pyrrolylspirocyclohexaneindolone II was prepd. from oxindole by deprotonation with butyllithium followed by addn. of 1,5-diiodopentane to give a spirocyclohexaneindolone; bromination with bromine in the presence of sodium acetate and acetic acid, palladium-catalyzed coupling of the bromospirocyclohexaneindolone with N-Boc-2-pyrroloboronic acid, nitration of the pyrrole nucleus with silver nitrate and acetyl chloride in acetonitrile, and thermal deprotection of the Boc protecting group gave II. II decreased the mass of the uterus of a treated rat over its control by 50% at 3 mg/kg. Biol. data for I are given.



IT 304875-78-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of oxospiro[cycloalkane-1,3'-indoline] derivs. and analogs)

as progesterone receptor antagonists

RN 304875-78-3 CAPLUS
 CN Spiro[cyclopropane-1,3'-(3H)indol]-2'-(1'H)-one, 5'-(3-chlorophenyl)- (9CI)
 (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB Title compds. [I: R1, R2 = H, OH, alkyl, alkoxy, (hetero)aryl, etc.; R1R2 = (CH2)n, O(CH2)m, O(CH2)pO, O, CH=CH2, etc.; R3 = H, OH, NH2, alk(en)yl,

10690802 6/16/06

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

26.93

194.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.75

-3.75

STN INTERNATIONAL LOGOFF AT 14:42:53 ON 16 JUN 2006